BRAF and cutaneous melanoma: Roughly half of the cutaneous melanomas have been shown to harbor a BRAF V600 mutation.1 For patients with advanced melanoma whose cancer harbors a BRAF V600E/K (BRAF V600) mutation, the optimal front‐line treatment is unknown.